# Clear blue skies and chilly breezes greet us today.

*biotech · news · 2026-05-26 · STAT*

## Key points

- Eli Lilly's gene-editing therapy reduced LDL cholesterol by 62% in a Phase 1 trial.
- There were no treatment-related serious adverse events reported in this early study.
- Lilly acquired this gene-editing therapy through its $1 billion buyout of Verve Therapeutics.
- Lilly's next step is a Phase 2 trial, with large Phase 3 trials likely required for approval.

**Companies:** Eli Lilly, Verve Therapeutics

[Read the full story on STAT](https://www.statnews.com/pharmalot/2026/05/26/lilly-gene-therapy-for-cholesterol-three-new-lilly-deals/)

---

Canonical: https://newsio.io/n/63c9111b-a8da-4038-8d95-e0e6c2dbb020/clear-blue-skies-and-chilly-breezes-greet-us-today-our-choice-today-is-strawberr
Summarized by Newsio from STAT. https://newsio.io/how-it-works